Novel germline TP53 variant (p.(Phe109Ile)) confers high risk of cancer.

MLA

Byrjalsen, Anna, et al. “Novel Germline TP53 Variant (p.(Phe109Ile)) Confers High Risk of Cancer.” Journal of Medical Genetics, vol. 61, no. 11, Nov. 2024, pp. 1023–25. EBSCOhost, https://doi.org/10.1136/jmg-2024-110255.

APA

Byrjalsen, A., Stoltze, U. K., Lautrup, C., Christensen, L. L., Mikkelsen, T., Hjalgrim, L., Brok, J. S., Dahl, C., Schmiegelow, K., Borgwardt, L., Diness, B. R., Van Overeem Hansen, T., & Wadt, K. A. W. (2024). Novel germline TP53 variant (p.(Phe109Ile)) confers high risk of cancer. Journal of Medical Genetics, 61(11), 1023–1025. https://doi.org/10.1136/jmg-2024-110255

Chicago

Byrjalsen, Anna, Ulrik Kristoffer Stoltze, Charlotte Lautrup, Lise Lotte Christensen, Torben Mikkelsen, Lisa Hjalgrim, Jesper Sune Brok, et al. 2024. “Novel Germline TP53 Variant (p.(Phe109Ile)) Confers High Risk of Cancer.” Journal of Medical Genetics 61 (11): 1023–25. doi:10.1136/jmg-2024-110255.